Market Cap 416.04M
Revenue (ttm) 198.77M
Net Income (ttm) -18.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.51%
Debt to Equity Ratio 0.00
Volume 2,472,300
Avg Vol 1,114,202
Day's Range N/A - N/A
Shares Out 59.10M
Stochastic %K 72%
Beta 0.69
Analysts Strong Sell
Price Target $11.75

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 734 3400
Fax: 202 296 1450
Address:
2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States
Trendrebel
Trendrebel Dec. 30 at 5:25 AM
$VNDA Today is the day, I personale valuate the most, Even that febr. PDUFA is better - on paper. But ( if...) todays approval has much more potential and appeal to partnership or buyout from level 1 companies. Its All about GLP-1. Novo is a perfect match with New approved pill and 30% nausea. Any investment in US will benefit Them acc. to tariffs. To partner up with VNDA, they will set back Eli Lilly, who actually need Tradipitant more, to catch up with Novo. On the other hand, Eli Lilly can use the rest of pipeline more than Novo. But there are more players on level II, who is desperate to get a share of the weight loss market. All GLP-1 have nausea problems. Remember 12 GLP-1 are approved so far. VNDA will be a hot pie here, if they cant solve the nausea problem. I guess there might be a line of offers coming in - within weeks. Cross fingers for an approval today. Tradipitant is worth much more than indicated. A $1B partnership is just a grip in the pocket.
1 · Reply
wshark
wshark Dec. 30 at 5:01 AM
$CORT $MREO $OTLK $PHIL $VNDA @cubie / chau is a freakish dishonest little ghoul….
1 · Reply
Gobler
Gobler Dec. 30 at 4:40 AM
$CORT $VNDA $MREO $OTLK $PHIL Don’t believe this person @cubie one second folks. He claims to have thousands of followers. 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️ Folks more than 90% of his followers are dormant accounts and many with recent joining. The proof is clear if you go to his followers list. Tons and tons of dormant accounts. One example from his followers list posted below. @MargRoss Keep scrolling folks, there tons of dormant accounts being added daily. What a fraud, caught in the act. I would never give @cubie any credibility. Lastly just search his name and he shows up numerous times. We all know what the means. I thought Luis was bad, this person takes the cake. 🎂 🤡🤡🤡🤡
1 · Reply
Seekinggold
Seekinggold Dec. 30 at 2:28 AM
$VNDA what is the target price to buy this stock?
1 · Reply
Flightstatus
Flightstatus Dec. 30 at 2:01 AM
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 30 at 12:37 AM
crowded atm, will buy when H% is low for $VNDA like I do for all others shown here
0 · Reply
CocaKolla
CocaKolla Dec. 30 at 12:24 AM
$VNDA you see the history, 2 times it’s try to break $30! We got strong buy and setups looks good and any days we got FDA news! Let’s sink in ⏰
0 · Reply
Camtanren
Camtanren Dec. 29 at 11:43 PM
$VNDA prob after hours tommorow for news
1 · Reply
Kukc
Kukc Dec. 29 at 11:11 PM
$VNDA could be massive move tomorrow
0 · Reply
BlackNYellow
BlackNYellow Dec. 29 at 11:01 PM
$VNDA Guess I’ll be waking up early tomorrow morning. May we all prosper in one way or another.
1 · Reply
Latest News on VNDA
Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 10:16 PM EDT - 2 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript


Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 10:29 PM EST - 11 months ago

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript


Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

Oct 14, 2024, 10:37 AM EDT - 1 year ago

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals


Trendrebel
Trendrebel Dec. 30 at 5:25 AM
$VNDA Today is the day, I personale valuate the most, Even that febr. PDUFA is better - on paper. But ( if...) todays approval has much more potential and appeal to partnership or buyout from level 1 companies. Its All about GLP-1. Novo is a perfect match with New approved pill and 30% nausea. Any investment in US will benefit Them acc. to tariffs. To partner up with VNDA, they will set back Eli Lilly, who actually need Tradipitant more, to catch up with Novo. On the other hand, Eli Lilly can use the rest of pipeline more than Novo. But there are more players on level II, who is desperate to get a share of the weight loss market. All GLP-1 have nausea problems. Remember 12 GLP-1 are approved so far. VNDA will be a hot pie here, if they cant solve the nausea problem. I guess there might be a line of offers coming in - within weeks. Cross fingers for an approval today. Tradipitant is worth much more than indicated. A $1B partnership is just a grip in the pocket.
1 · Reply
wshark
wshark Dec. 30 at 5:01 AM
$CORT $MREO $OTLK $PHIL $VNDA @cubie / chau is a freakish dishonest little ghoul….
1 · Reply
Gobler
Gobler Dec. 30 at 4:40 AM
$CORT $VNDA $MREO $OTLK $PHIL Don’t believe this person @cubie one second folks. He claims to have thousands of followers. 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️ Folks more than 90% of his followers are dormant accounts and many with recent joining. The proof is clear if you go to his followers list. Tons and tons of dormant accounts. One example from his followers list posted below. @MargRoss Keep scrolling folks, there tons of dormant accounts being added daily. What a fraud, caught in the act. I would never give @cubie any credibility. Lastly just search his name and he shows up numerous times. We all know what the means. I thought Luis was bad, this person takes the cake. 🎂 🤡🤡🤡🤡
1 · Reply
Seekinggold
Seekinggold Dec. 30 at 2:28 AM
$VNDA what is the target price to buy this stock?
1 · Reply
Flightstatus
Flightstatus Dec. 30 at 2:01 AM
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 30 at 12:37 AM
crowded atm, will buy when H% is low for $VNDA like I do for all others shown here
0 · Reply
CocaKolla
CocaKolla Dec. 30 at 12:24 AM
$VNDA you see the history, 2 times it’s try to break $30! We got strong buy and setups looks good and any days we got FDA news! Let’s sink in ⏰
0 · Reply
Camtanren
Camtanren Dec. 29 at 11:43 PM
$VNDA prob after hours tommorow for news
1 · Reply
Kukc
Kukc Dec. 29 at 11:11 PM
$VNDA could be massive move tomorrow
0 · Reply
BlackNYellow
BlackNYellow Dec. 29 at 11:01 PM
$VNDA Guess I’ll be waking up early tomorrow morning. May we all prosper in one way or another.
1 · Reply
FelixH86
FelixH86 Dec. 29 at 10:12 PM
0 · Reply
Dragan7
Dragan7 Dec. 29 at 10:03 PM
$VNDA TD Web-Broker: Analyst Ratings Sell 0 Hold 0 Buy 3 3 analysts | Overall: Strong Buy As of 29 Dec 2025, 04:00:00 p.m. ET Vanda Pharmaceuticals Stock Forecast: Stock Price Forecast The 3 analysts that cover Vanda Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14, which forecasts a 94.44% increase in the stock price over the next year. The lowest target is $11 and the highest is $20. Price Target: $14 (+94.44%) https://stockanalysis.com/stocks/vnda/forecast/ $14.00 ▲(94.44% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Vanda in the last 3 months. The average price target is $14.00 with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 94.44% change from the last price of $7.20. https://www.tipranks.com/stocks/vnda/forecast
0 · Reply
Dragan7
Dragan7 Dec. 29 at 9:52 PM
$VNDA Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with FDA: October 1, 2025 "Key features of the agreement include: The FDA will conduct an expedited re-review of the partial clinical hold preventing long term clinical studies of tradipitant for the treatment of motion sickness by November 26, 2025. The FDA will continue its review of Vanda's New Drug Application (NDA) for this indication, with the existing Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025. The FDA will conduct an expedited re-review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® for the treatment of jet lag disorder by January 7, 2026, including consideration of alternative or narrowed indications focusing on the sleep-related aspects of jet lag disorder".........
0 · Reply
cubie
cubie Dec. 29 at 9:44 PM
$CORT $VNDA $MREO $OTLK Cubie teaches, thats why got so many followers 😚😏. No one does research like cubie
1 · Reply
Rj260192
Rj260192 Dec. 29 at 9:42 PM
$VNDA 5th Trending
0 · Reply
Stanleydavidson
Stanleydavidson Dec. 29 at 9:25 PM
$VNDA Lets mske 30%-50%-100% or loose 20%
0 · Reply
NYC100
NYC100 Dec. 29 at 9:24 PM
$OTLK $VNDA I have both 🎉🎉
1 · Reply
cubie
cubie Dec. 29 at 9:22 PM
$CORT interesting 😅. $VNDA $OTLK meh😅
1 · Reply
Stanleydavidson
Stanleydavidson Dec. 29 at 9:22 PM
$VNDA lot of chicken from 3h30-4🤣
0 · Reply
Stanleydavidson
Stanleydavidson Dec. 29 at 8:59 PM
$VNDA lot of chiken at tge end
0 · Reply
Lucas_Ward_
Lucas_Ward_ Dec. 29 at 8:58 PM
$VNDA Small cap biotech, under the radar coil, volume ignition is needed for confirmation
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 29 at 8:54 PM
Comparing trending tickers $VNDA vs $SOUN: VNDA has risen to $7.28, showing a 3.41% increase, with 2.1 million shares traded, significantly above its average of 660K. In contrast, SOUN dropped 3.64% to $10.31 with a trading volume of 17.8 million shares, which is much lower than its usual 43.4 million. VNDA is performing well today with a notable rise and higher-than-average trading volume, while SOUN's price has fallen despite a substantial number of shares changing hands, though below its average trading activity.
0 · Reply